Desire and Function Are Not the Same Problem

Desire and function are not the same system

Function is plumbing and wiring. An erection is a vascular event: arousal signals travel down nerves, smooth muscle in the arteries relaxes, blood enters faster than it leaves, and the tissue does the rest. Every part of that can fail independently — the nerves after pelvic surgery, the arteries in diabetes or atherosclerosis, the signal itself under the influence of a medication. In women the same machinery exists and is less often discussed: genital blood flow, lubrication and tissue elasticity are physical responses with physical causes.

Desire is brain. It runs on motivation and reward circuitry, on hormonal tone, and on everything feeding those — sleep, mood, stress, alcohol, medication, and the ordinary context of a life. It is not a readout of how much you like your partner, and it is not a number that can be checked against anyone else's.

Between them sits arousal, which belongs to both and confuses the picture. Genital response and subjective desire correlate poorly, especially in women: the body can respond while nothing much is felt, and desire can be entirely present while the body does not cooperate. So the first useful question in a consultation is never how bad is it — it is which of the two changed, and what changed at the same time. Everything downstream, including whether a prescription is the right answer, follows from that. Low libido and erectile changes at 50 are separate conversations for exactly this reason.

What actually changes, and when

In men, the change is usually gradual and mechanical before it is hormonal. Erections become more dependent on direct stimulation and less spontaneous. Morning erections thin out. The interval before a second one lengthens, sometimes considerably. None of that is a disease, and describing it as one has sold a great deal of medicine. Testosterone declines slowly through midlife — on average around one percent a year from the forties — which is a different curve from the cliff women encounter, and it is slow enough that a level is only interpretable alongside symptoms.

In women, the change is faster and more clearly dated. Falling estradiol through perimenopause and after thins the vulvovaginal tissue, reduces blood flow and elasticity, and shortens natural lubrication — physical changes with a physical treatment, covered below. Testosterone and DHEA, meanwhile, decline steadily from the twenties rather than dropping at menopause, so a woman whose desire changed at 51 is rarely looking at a testosterone event. What often did change at 51 is sleep: night sweats fragment it, and fragmented sleep suppresses desire in everyone.

In both, the quieter driver is accumulation. Vascular aging, a longer medication list, a heavier weight, more alcohol than at 30, a condition or two that was not there before. Sexual function is downstream of general health, which is why it is one of the more informative things anyone mentions in an appointment and one of the last things anyone mentions.

The causes worth excluding before anything is prescribed

Most of what shows up as a sexual complaint in midlife has a cause upstream of it, and the short list is boring, common and largely measurable: cardiovascular disease, diabetes and insulin resistance, obstructive sleep apnea, thyroid dysfunction, genuinely low testosterone, depression, alcohol, and medication side effects. Several of them are visible on a baseline panel; the rest come out of a history taken properly.

Medications deserve naming, because in this age group they are so often the whole answer and so rarely the first thing checked. Antidepressants — the SSRIs and SNRIs in particular — reduce desire, delay or block orgasm, and do so commonly rather than rarely; the effect is frequently manageable by changing the agent, which is a conversation with the prescribing clinician rather than a reason to stop anything abruptly. Finasteride, taken for hair loss or for prostate symptoms, is reported to affect desire and erectile function in a minority of men. Several antihypertensives, notably older beta-blockers and thiazide diuretics, do the same, and there are alternatives within the same job. Opioids suppress testosterone directly.

The single most common reversible cause we see is a medication list that nobody has reviewed against this symptom — partly because patients do not connect the two, and partly because the symptom does not get raised. Low Libido in Midlife: The Causes Worth Ruling Out First goes through the list in detail.

Erectile difficulty is a vascular finding first

This is the most important thing on this page, and it is the point the category is structured to skip.

An erection depends on the endothelium — the lining of the blood vessels — relaxing on cue. Atherosclerosis damages endothelial function everywhere at once, but it does not become visible everywhere at once. The penile arteries are narrower than the coronary arteries, so the same degree of narrowing produces a noticeable symptom there first. In a substantial share of men who go on to have a cardiac event, erectile difficulty appeared years earlier. It is, in the plainest terms, a stress test nobody ordered.

The clinical implication is uncomfortable for a business that sells tablets. A PDE5 inhibitor removes the symptom without touching the disease — and in doing so removes the one thing that would have sent that man to have his blood pressure, his lipids, his glucose and his smoking status looked at. The tablet is not the problem; the tablet instead of the panel is.

So new erectile difficulty in a man over 45 is a reason to check cardiovascular risk properly, not a reason to check nothing. It is also worth saying that the association runs the other way as well: treating blood pressure, glucose and weight improves erectile function for the same reason it improves everything else. Erectile Changes at 50: What Is Common and What Is Worth Investigating sets out where the line between ordinary and investigable sits.

The women's side, on its own terms

Genitourinary syndrome of menopause is the current name for a cluster that used to be called vaginal atrophy, and the rename was not cosmetic: the condition covers dryness, burning, irritation, loss of elasticity, urinary urgency and recurrent urinary tract infections, because the tissue of the vulva, vagina, urethra and bladder all depends on estrogen. It affects a large proportion of women after menopause. Unlike hot flashes, it does not settle with time — left alone, it progresses.

Which means pain with sex is usually a tissue problem, not a psychological one. That distinction has been got wrong so consistently, and for so long, that many women arrive having already concluded the problem is in their head. It generally is not. Pain reliably suppresses desire, and that suppression is a correct response to pain rather than a disorder of desire — so treating the pain often resolves what was being labeled low libido. Vaginal estrogen is the best-evidenced treatment for this: it acts locally on the tissue, with very little reaching the bloodstream, which is why its risk profile differs from systemic hormone therapy. Non-hormonal moisturizers and lubricants help too, and pelvic floor physical therapy is genuinely useful where muscle tone is part of it.

The other correction worth making is about desire itself. For a great many women — and plenty of men — desire is responsive rather than spontaneous: it arrives after arousal and context rather than announcing itself first. Spontaneous desire is one pattern, not the definition of a healthy one, and a woman measured against a template that was never universal will be told something is broken when nothing is. Low desire is worth treating when she is distressed by it. It is not a deficit to be corrected on anyone else's behalf.

Where distressing low desire persists after menopause and the treatable causes have been addressed, testosterone in women is used off-label, with evidence supporting an effect on desire and no product approved for women in the United States. Menopause and hormone therapy for women cover the wider picture.

The part no prescription reaches

Context is an input, not a consolation prize offered when the labs come back clean. Twenty-five years with the same person, a parent in decline, a job that ended, a diagnosis in the house, resentment nobody has said out loud, or simply a long-standing mismatch in who initiates — all of these change desire, and none of them is a hormone problem wearing a disguise.

Desire discrepancy between two people is the most common presentation in couples work and is not a disease in either of them. One partner is not broken for wanting less and the other is not wrong for wanting more; what is treatable is the part that has a cause, and what is negotiable is the rest.

Nor are the physical and the psychological rivals. Performance anxiety produces exactly the sympathetic tone that opposes the parasympathetic signaling an erection needs, so a mechanical failure creates an anxiety that then reproduces the mechanical failure. Breaking that loop sometimes takes a tablet and a conversation rather than one or the other. And reduced desire is an early symptom of depression as well as a side effect of treating it — a distinction worth making carefully, because the two point in opposite directions.

What each option can and cannot do

PDE5 inhibitors — tadalafil, sildenafil and their relatives — relax vascular smooth muscle so that more blood enters in response to arousal. They are FDA-approved, generic, inexpensive, and supported by two decades of randomized trials, which makes them by a wide margin the best-evidenced thing in this category. They do nothing for desire, and expecting otherwise is the most common misunderstanding about the whole drug class.

The nitrate rule is absolute. A PDE5 inhibitor taken with any nitrate — nitroglycerin in any form, isosorbide mononitrate or dinitrate, or amyl nitrite (“poppers”) — can cause a severe and potentially fatal drop in blood pressure. This is a contraindication, not a risk to be weighed against benefit. Anyone who carries nitroglycerin for chest pain cannot take these, and anyone who has taken one should tell an emergency clinician, because it changes what can safely be given. Alpha-blockers and other blood pressure medication need review rather than exclusion.

Testosterone is a desire treatment, not an erection treatment. Where a man is genuinely low and symptomatic, replacing it can restore drive, energy and mood, and it may improve erectile function indirectly — but it does not reliably fix an erection, and prescribing it for that alone is treating the wrong system. It is monitored therapy, not a one-off. Testosterone therapy for men covers how it is decided and tracked.

PT-141 (bremelanotide) acts centrally on melanocortin receptors, which puts it on the desire side rather than the blood flow side. It is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Any other use — in men, in postmenopausal women, or as part of a compounded combination — is outside that approval, and compounded preparations are not reviewed by the FDA for safety or effectiveness. Nausea and flushing are common, and it is not appropriate with uncontrolled blood pressure or known cardiovascular disease. Who Should Not Take PT-141 is the honest version of that list.

Oxytocin is prescribed in this category as a compounded preparation and is not FDA-approved for it; the evidence for an effect on desire or intimacy is thin, and What Oxytocin Does, Beyond the Headlines separates what is demonstrated from what is claimed.

And treating the cause belongs on this list rather than beneath it: the CPAP machine, the switched antidepressant, the vaginal estrogen, the glucose brought under control, the drink fewer nights a week. None of them is billed as a sexual treatment and all of them work like one. No option here, ours included, comes with a guaranteed outcome — what can be promised is that we find out what changed before deciding what to do about it.

Frequently asked questions